Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Improving Efficiency Of Surveillance Colonoscopy For Colorectal Cancer Prevention
Funder
National Health and Medical Research Council
Funding Amount
$643,123.00
Summary
Greater awareness of bowel cancer screening has led to increased demand and waiting times for colonoscopy. National guidelines recognise the need for research to identify the best use of colonoscopy to ensure health funds are directed where they are needed. This study aims to identify how often colonoscopy is required for the best patient outcomes. Data about cancer and death will be linked to hospital and laboratory data to identify which patients need more or less surveillance colonoscopies.
Post-stroke Hyperglycaemia – Treatment With Exenatide In Acute Ischaemic Stroke (TEXAIS) Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,266,149.00
Summary
Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse outcomes. Insulin is not useful as a treatment for this as it causes frequent hypoglycaemia and does not improve clinical outcomes. Exenatide is a common diabetes drug that is simple to use and lowers blood glucose without hypoglycaemia. It will be tested in the Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial.
Preventing Hospital Readmission In A Regional Australian Hospital Setting
Funder
National Health and Medical Research Council
Funding Amount
$565,695.00
Summary
Hospitals face high levels of emergency presentations and demand for inpatient care particularly for Aboriginal Australian people from remote communities. Readmissions lead to overcrowded emergency departments and poorer patient outcomes. We will evaluate the efficacy of a multidimensional case-based management intervention linking hospital and primary health in a regional Australian hospital with the aim of reducing hospital readmission and improving patient outcomes.
Impact Of Advanced Glycation On Anti-atherogenic Properties Of High Density Lipoprotein
Funder
National Health and Medical Research Council
Funding Amount
$372,471.00
Summary
Type 2 diabetes is a rapidly growing medical problem in Australia and around the world. Diabetes affects human health through its complications and the cardiovascular complications are a cause for major concern. One of the complications is the effect on plasma lipids: it makes cholesterol carrying particles to accumulate in the blood vessels, causing atherosclerosis. We intend to investigate how diabetes modify these particles making them atherogenic.
An Integrated Approach To Identify The Molecular Mechanisms Contributing To The Pathogenesis Of Insulin Resistance: Targeting The Liver And Skeletal Muscle
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The inability of muscle and liver to utilise sugar from the blood is a major problem that contributes to the development of obesity and diabetes. How these problems occur is unknown. The goal of my research is to identify what causes the muscle and liver problem, and whether fixing these problems will reduce obesity and diabetes. Since the number of people with obesity and diabetes is predicted to double over the next decade, we need to understand the cause of these diseases.
Central Neural Regulation Of Brown Fat Function – Glucose Sensing And CNS Pathways
Funder
National Health and Medical Research Council
Funding Amount
$761,942.00
Summary
Our research aims to identify how specific brain cells detect changes in glucose levels and how ageing and diet affect their function. We identified a subset of nerve cells that detect changes in glucose and the “hunger” hormone ghrelin, their ability to do so adapting with age and nutritional status. This project will investigate the potential of these nerve cells as targets for therapeutic and diet- intervention strategies to target obesity, diabetes and promote healthy ageing.
Identifying Factors That Improve The Health Of Prisoners Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$376,658.00
Summary
Prisoners who inject drugs are highly marginalised with high rates of unresolved health and social issues and high rates of return to prison. Little is known, however, about how this group manages after release from prison. This qualitative project will allow ex-prisoners to tell their own stories of the challenges they have had and what strategies (formal and informal) they have used with the aim of informing responses in prisons and in the community setting.
SGLT2 inhibitors are new glucose-lowering agents for type 2 diabetes. They promote glucose loss into urine, which lowers blood glucose levels. However, little is known regarding the changes to kidney physiology when this system is manipulated with these drugs. There is evidence that SGLT2 inhibitors do not protect against kidney disease in diabetic mice, despite being an effective blood glucose-lowering agent. I aim to characterise the changes to kidney function upon SGLT2 blockade in diabetes.
Biology Of EGFR Mutations In Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$287,445.00
Summary
The epidermal growth factor receptor (EGFR) is a protein that has a critical role in the development of normal cells. In glioma, the most lethal of the brain cancers, the EGFR is altered. These alterations result in uncontrolled activation of the EGFR, causing signals that promote the growth and survival of brain cancer. This grant seeks to understand the nature of the signals mediated by the altered EGFR, in turn helping us develop better therapeutics for the treatment of this deadly cancer.